Compare Amphastar Pharmaceuticals Inc (AMPH) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Kohl's Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Kohl's Corporation trades at $18.49 (market cap $2.16B). The key difference: Kohl's Corporation is far larger — about 2.5× Amphastar Pharmaceuticals Inc's market cap, and Kohl's Corporation pays a 2.63% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | KSS | |
|---|---|---|
Market Cap | $863.95M | $2.16B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $24.71 |
52-Week Low | $16.87 | $11.72 |
Enterprise Value | $1.26B | $8.26B |
Dividend Yield | — | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Kohl's (KSS) trades at $19.30, up 4.54% in the last session, with a bullish technical signal from moving averages. The stock shows attractive valuation ratios, including a P/E of 8.11 and P/B of 0.54, but faces revenue declines from $16.22B in 2025 to an expected $15.5B in 2026. Recent Q1 2026 earnings beat estimates, and the company appointed a new COO to drive operational improvements.
The outlook is mixed: low valuations and earnings beats offer upside, but persistent sales drops and thin net margins near 1.77% pose risks. Analyst consensus is cautious with a $16.75 price target below the current price, reflecting concerns over competitive pressures and cash flow volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
